Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

InspireMD (NSPR) Stock Price & Analysis

710 Followers

NSPR Stock Chart & Stats

$0.70$0.06(8.92%)
At close: 4:00 PM EST
$0.5$0.75$1Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$0.61 - $0.72
52-Week Range
$0.43 - $2.22
Previous Close
$0.64
Volume
N/A
Average Volume (3M)
272.24K
Market Cap
$32.36M
Enterprise Value
$31.87M
Total Cash (Recent Filing)
$30.42M
Total Debt (Recent Filing)
$1.97M
Price to Earnings (P/E)
―
Beta
-0.42
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
-0.15
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage gives InspireMD more financial flexibility than a heavily indebted loss-making medtech company. Limited debt reduces mandatory financing costs and creditor pressure, allowing available capital to remain focused on clinical development, regulatory work, and commercialization.

International Revenue Growth

International growth indicates that CGuard is gaining physician adoption and generating demand outside the temporarily paused U.S. market. Continued overseas expansion can diversify revenue, validate the product platform, and provide a commercial base while U.S. regulatory milestones remain pending.

Regulatory And Product Pipeline

Multiple regulatory and product milestones create several potential routes to expand InspireMD's addressable market. Approval of Prime 80, relaunch of Prime 135, and progress on SwitchGuard could strengthen the platform's commercial reach and support a more durable U.S. revenue opportunity.

Bears Say

Persistent Cash Burn

Heavy operating and free-cash-flow deficits show that InspireMD is not yet self-funding and continues to consume capital to operate and develop its products. Sustained cash usage can constrain execution, increase reliance on financing, and heighten sensitivity to delays in approvals or revenue recovery.

Severe Unprofitable Cost Structure

Losses remain extremely large relative to the company's revenue base, while gross profitability is modest. This indicates that the current operating structure is far from breakeven, making future profitability dependent on substantial revenue scaling, cost reductions, and successful commercialization.

Recall And Liquidity Pressure

The voluntary recall has disrupted U.S. commercialization, damaged reported gross margin, and reduced available liquidity through credits, inventory impairment, and ongoing losses. Until products return to market and revenue improves, the company remains exposed to execution and funding pressure.

InspireMD News

NSPR FAQ

What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was $0.43 and its highest was $2.22 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is $32.36M.
When is InspireMD’s upcoming earnings report date?
InspireMD’s next earnings report is estimated for Nov 12, 2026 (not yet confirmed), which is in 2 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on Aug 17, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.03.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -0.15.
How many shares outstanding does InspireMD have?
InspireMD has 46,489,117 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -10.489%.
Which hedge fund is a major shareholder of InspireMD?
Hedge funds hold InspireMD shares: the largest hedge-fund position in InspireMD is 71,885,285 shares, and hedge funds increased their holdings by 42.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology